Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Athira Pharma (ATHA)
NASDAQ:ATHA
Holding ATHA?
Track your performance easily
ATHA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.41 - $4.30
Previous Close$0.61
Volume7.76M
Average Volume (3M)4.70M
Market Cap
$23.29M
Enterprise Value-$67.07M
Total Cash (Recent Filing)$91.77M
Total Debt (Recent Filing)$1.41M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Nov 07, 2024EPS Estimate
-$0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.97
Shares Outstanding38,439,375
10 Day Avg. Volume25,853,171
30 Day Avg. Volume4,702,999
Standard Deviation0.28
R-Squared0.24
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.29
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.78
Forecast
1Y Price Target
$0.58Price Target Upside-9.36% Downside
Rating ConsensusHold
Number of Analyst Covering5
Athira Pharma News
PremiumMarket News
3 Penny Stocks to Watch Now, 11/5/24
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentFosgonimeton showed directional improvements in validated biomarkers for Alzheimer's disease and neurodegeneration, indicating its potential efficacy.
Financial StrategyRestructuring efforts announced by the company are expected to lead to approximately $13 million of annualized cost savings.
Market OpportunityATHA's novel biology platform targets large neurodegenerative disease markets, including Alzheimer's disease and ALS.
Bears Say
Clinical TrialsThe Phase 2/3 LIFT-AD trial did not meet its primary or key secondary endpoints, casting doubt on the efficacy of the treatment under investigation.
Financial PerformanceThe stock experienced a significant decline, trading at approximately 35% of its cash value, indicating a potential lack of investor confidence.
Investor SentimentInvestor sentiment on ATHA is bearish, as the HGF/MET approach is poorly understood and remains largely unproven, leading to skepticism in the market.
---
Ownership Overview
24.22% Insiders
6.23% Mutual Funds
1.47% Other Institutional Investors
59.71% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATHA FAQ
What was Athira Pharma’s price range in the past 12 months?
Athira Pharma lowest stock price was $0.41 and its highest was $4.30 in the past 12 months.
What is Athira Pharma’s market cap?
Currently, no data Available
When is Athira Pharma’s upcoming earnings report date?
Athira Pharma’s upcoming earnings report date is Nov 07, 2024 which is in 2 days.
How were Athira Pharma’s earnings last quarter?
Athira Pharma released its earnings results on Aug 01, 2024. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.737 by $0.037.
Is Athira Pharma overvalued?
According to Wall Street analysts Athira Pharma’s price is currently Overvalued.
Does Athira Pharma pay dividends?
Athira Pharma does not currently pay dividends.
What is Athira Pharma’s EPS estimate?
Athira Pharma’s EPS estimate is -$0.7.
How many shares outstanding does Athira Pharma have?
Athira Pharma has 38,439,377 shares outstanding.
What happened to Athira Pharma’s price movement after its last earnings report?
Athira Pharma reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.737. Following the earnings report the stock price went down -1.231%.
Which hedge fund is a major shareholder of Athira Pharma?
Among the largest hedge funds holding Athira Pharma’s share is Perceptive Advisors LLC. It holds Athira Pharma’s shares valued at 14M.
---
Athira Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.58 (-9.36% Downside)
$0.58 (-9.36% Downside)
Hedge Fund Trend
Increased
By 27.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.7%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.42%
12-Months-Change
Fundamentals
Return on Equity
-84.57%
Trailing 12-Months
Asset Growth
-46.53%
Trailing 12-Months
Company Description
Athira Pharma
Athira Pharma Inc is a bio-technology company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company is developing treatments for Alzheimer's disease and Parkinson's disease.
---
ATHA Stock 12 Month Forecast
Average Price Target
$0.58
▼(-9.36% Downside)
Technical Analysis
---